Render Target: STATIC
Render Timestamp: 2024-12-26T11:40:25.817Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:56:09.206
Product last modified at: 2024-12-17T18:58:37.790Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD47 (D3O7P) Rabbit mAb #63000

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 45-50
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    IHC Leica Bond 1:100 - 1:400
    Immunohistochemistry (Paraffin) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #97253.

    Protocol

    Specificity / Sensitivity

    CD47 (D3O7P) Rabbit mAb recognizes endogenous levels of total CD47 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu72 of human CD47 protein.

    Background

    CD47 is a five-pass transmembrane protein expressed on all normal cells. It binds to the SIRPα that is expressed on myeloid cells, including macrophages, and neuronal cells in the central nervous system. Binding of CD47 to SIRPα promotes phosphorylation of tyrosine residues in the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within the SIRPα cytoplasmic tail, inhibiting macrophage phagocytosis toward CD47-expressing cells. In this way, CD47 serves as a "don't eat me" signal or a marker of "self", functioning as an innate immune checkpoint. Additionally, CD47 was reported to modulate lymphocyte cell activation and proliferation (1-3). CD47 is overexpressed in many types of cancer. The expression level of CD47 on cancer cells is negatively associated with the response to therapies, and low expression on tumor cells is associated with a better prognosis and survival. Reagents that can block CD47-SIRPα interaction are being actively pursued for therapeutic applications (4,5). In addition to SIRPα, other proteins have been reported to bind to CD47. Thrombospondin-1 (TSP1) competes with SIRPα to bind to CD47 in the extracellular region and activates signaling pathways downstream of CD47 (6). CD47 can laterally associate with VEGFR2, FAS, and certain integrins in different contexts, and influences their downstream signaling (7-9). CD47 can be shed from the cell surface by proteolytic cleavage. In addition, CD47 is present on extracellular vesicles including exosomes, suggesting additional extracellular signaling potential (10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.